drugset / Trial / NCT07283315
Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases
Phase 0
Recruiting
12 enrolled
The Children's Hospital of Zhejiang University School of Medicine
Rui Therapeutics Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
Evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Paediatric B cell-related autoimmune diseases
Timeline
- Start
- 2025-12-03
- Primary completion
- 2028-12-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KN5601-K | Cell therapy | — | Other |